

Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/BE9A417F592BEN.html>

Date: August 2022

Pages: 245

Price: US\$ 2,000.00 (Single User License)

ID: BE9A417F592BEN

Abstracts

Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 24, 13, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development

Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones

Featured News & Press Releases

Jul 12, 2022: Turn Therapeutics announces positive in-vivo data for non-melanoma skin cancer candidate

Jul 11, 2022: MediWound announces positive initial data from its U.S. Phase I/II Study of MW005 for the treatment of basal cell carcinoma

Apr 05, 2022: Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals triggered by first patient dosed with LTX-315

Apr 05, 2022: Verrica Pharmaceuticals announces first patient dosed in phase 2 study of LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma

Mar 28, 2022: At the 2022 AAD Annual Meeting, Senhwa presents positive initial data from clinical trial of Silmitasertib used to treat patients with advanced basal cell carcinoma

Feb 23, 2022: Sirnaomics announces interim data from phase II clinical trial of STP705 for treatment of Cutaneous Basal Cell Carcinoma

Feb 01, 2022: Biofrontera provides update on patient recruitment for phase III study for the treatment of sBCC with Ameluz-PDT

Dec 16, 2021: Senhwa clinical data abstract for silmitasertib in patients with advanced basal cell carcinoma accepted for 2022 AAD Annual Meeting

Nov 18, 2021: Verrica Pharmaceuticals announces FDA acceptance of its IND application for LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma

Oct 29, 2021: Libtayo (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma

Jul 26, 2021: MediWound announces initiation of U.S. phase I/II study of MW005 for the treatment of basal cell carcinoma

Jun 25, 2021: Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Jun 07, 2021: MediWound announces peer-reviewed paper of a case series report of basal cell carcinoma published in the Open Dermatology Journal

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, 2022

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/BE9A417F592BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE9A417F592BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

